Dendreon’s Provenge Gets FDA Approval – Now What?
We have been closely following Dendreon (DNDN) since back in 2003 when they had their first successful Phase 3 results for their immunotherapy treatment for prostate cancer, then known as sipuleucel-T.
Provenge, as it is now called, was finally approved by the FDA Thursday. Provenge is a whole new paradigm for treatment: instead of directly attacking the cancer, it "trains" the body’s own immune system to do the job. So far, Provenge has only been tested in men with advanced cancer (and weaker immune systems) and the fact that it positively effects survival in that population could be an indication that it may be even more effective when given to earlier-stage patients (with stronger immune systems).
Investing, Long Term Investment, stock market | admin April 30, 2010
RSS feed for comments on this post.
